Meropenem pharmacokinetic/pharmacodynamic target attainment and clinical response in intensive care unit (ICU) patients: A prospective observational study
Authors' conclusion
Intermittent meropenem bolus infusion q6h gives satisfactory TA in an ICU population with variable renal function and CRRT modality, except for ARC patients. No consistent relationship between TA and clinical endpoints were observed.
Study context
- Population
- ICU patients ≥18 years receiving intermittent bolus meropenem (mainly 1 g q6h), 2014–2017
- Participants
- 87 patients
- Exposure
- Normal renal clearance (NRC) vs augmented renal clearance (ARC) vs continuous renal replacement therapy (CRRT)
- Outcome
- Meropenem PK/PD target attainment (100% T > 4× MIC or trough above 4× MIC)
- Follow-up
- 24, 48 and 72 h after therapy initiation
Main finding
As reported in the abstract
Median TA
ARC
45.5%
median
Observational data: associations, not effects.
Further findings
C-reactive protein (CRP), total population · first 72 h
- Median CRP fell from 175 (IQR, 88-257) to 70 (IQR, 30-114)
- P < 0.001
Sequential Organ Failure Assessment (SOFA) score
- Reduction in SOFA score only in the non-CRRT groups
- P < 0.001
90-day mortality
- 90 days mortality rate (median Simplified Acute Physiology (SAPS) II 37)
- 32%
Original publication
Meropenem pharmacokinetic/pharmacodynamic target attainment and clinical response in ICU patients: A prospective observational study. Acta Anaesthesiol Scand. Published 29 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →